Related Experiment Video

Updated: Jul 3, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Prolonged response to gefitinib in bone metastasis

Hiroaki Satoh1, Hiroichi Ishikawa, Gen Ohara

  • 1Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki 305-8575, Japan. hirosato@md.tsukuba.ac.jp

Medical Oncology (Northwood, London, England)
|July 9, 2008
PubMed
Summary

No abstract available in PubMed .

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Experiment Videos

Last Updated: Jul 3, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Articles linked to this work by shared authors, journal, and citation graph.

Short-term changes in serum total protein and albumin and clinical outcomes in acute exacerbation of interstitial lung diseases.

Tuberkuloz ve toraks·2026

Clinical remission in elderly patients with sarcoidosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026

Pleuroparenchymal Fibroelastosis With a Nodular Shadow Considered To Be Rounded Atelectasis: A Case Report.

Respirology case reports·2026

Leptomeningeal Metastasis in Patients With EGFR-positive NSCLC: A Propensity-matched Retrospective Study of Patients With EGFR-negative NSCLC.

Anticancer research·2026

Dose Reduction of EGFR-TKIs for EGFR-positive Non-small Cell Lung Cancer: A Retrospective Study.

Cancer diagnosis & prognosis·2025

A Case of Pleuroparenchymal Fibroelastosis.

Prague medical report·2025

Survivin mRNA lipid nanoparticles and CTLA-4 inhibitor co-delivery activates anti-tumor cytotoxic T-lymphocytes for oral cancer immunotherapy.

Medical oncology (Northwood, London, England)·2026

Iron oxide nanoparticles co-conjugated with hyaluronic acid and limonene trigger oxidative stress and cell cycle arrest in triple-negative breast cancer.

Medical oncology (Northwood, London, England)·2026

Lipid peroxidation in cancer: a double-edged sword shaping progression and therapy.

Medical oncology (Northwood, London, England)·2026

Development and validation of a nomogram for predicting venous thromboembolism risk in colorectal cancer patients undergoing postoperative chemotherapy.

Medical oncology (Northwood, London, England)·2026

Current status and challenges of immune checkpoint inhibitors in liver cancer: from monotherapy to combination strategies.

Medical oncology (Northwood, London, England)·2026

Genomic, transcriptomic, and molecular predictors of response to neoadjuvant therapy in locally advanced rectal cancer: a narrative review.

Medical oncology (Northwood, London, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us